AbbVie Inc.
$505.52B- Market cap
- $445.76B
- Debt
- +$65.00B
- Cash
- −$5.23B
Capital structure 87% equity / 13% debt · EV / Revenue 8.27x · EV proxy / EBITDA proxy 21.78x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $445.76B · View financials
Snapshot Sep 10, 2026, 9:41 AM ET
Decision snapshot: ABBV stock price vs BDX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BDX's multiple
Needs BDX P/E.
Implied fair value · at ABBV's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 87% equity / 13% debt · EV / Revenue 8.27x · EV proxy / EBITDA proxy 21.78x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AbbVie Inc. · implied price per share
Bear
$87.89
Base
$110.94
Bull
$142.98
BECTON, DICKINSON AND COMPANY · implied price per share
Bear
$42.31
Base
$61.15
Bull
$85.69
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABBV deserves a very large premium to BDX despite the much higher P/E and P/S multiples, then hold or accumulate only on confidence in that premium narrowing over time; otherwise, the data argues for avoiding new buys because ABBV is priced far above both BDX-implied and DCF ranges.
ABBV’s current price of $250.94 is far above BDX-implied price of $67.16, implying -73.2% downside versus BDX-based valuation. The gap is driven by ABBV trading at much richer earnings and sales multiples than BDX, while the provided range data suggests the stock is also well above BDX-implied band.
Supporting Metrics